Neogenomics Inc. NEO

Precision Instruments · data as of November 13, 2026

$16.02Market cap $2.1B

Neogenomics Inc. (NEO) is a healthcare company listed in the US with a market value of about $2.1B. In the twelve months to September 30, 2026 it had revenue of $788M and net income of -$32M, a net margin of -4.1%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.

Score: 0.8 / 5

Value0/5

Future growth2/5

Track record1/5

Financial health1/5

Shareholder returns0/5

Checks passed

Revenue growth above 10% last year
3-year revenue growth above 10% a year
5-year revenue growth above 8% a year
Liabilities below 60% of assets

Checks not passed

P/E below 25
P/E below the industry median
P/FCF below 20
Price below intrinsic value (DCF, moderate assumptions)
PEG below 1.5
Profit margin improving
3-year free cash flow growth above 10% a year
Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—

Forward P/E58.1

P/FCF—

P/S2.6

P/B2.6

EV/EBITDA128.8

PEG—

Dividend yield0.00%

FCF yield-1.4%

Shareholder yield0.0%

Intrinsic value vs. price−84%

Growth and quality

Revenue growth (1 yr)10.1%

Revenue growth (5 yrs, per year)10.3%

EPS growth (5 yrs, per year)—

FCF growth (3 yrs, per year)—

Net margin (5-yr avg.)-14.3%

ROIC (5-yr avg.)-6.8%

Profitable years (of last 10)3

Years paying a dividend—

Financials, last 10 years

Fiscal year	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$788M	$727M	$661M	$592M	$510M	$484M	$444M	$409M	$277M	$240M	$232M
Net income	-$32M	-$108M	-$79M	-$88M	-$144M	-$8M	$4M	$8M	$3M	-$396000	-$6M
Free cash flow	-$29M	-$22M	-$34M	-$31M	-$97M	-$91M	-$28M	$3M	$30M	$4M	$14M
EPS (diluted)	$-0.24	$-0.84	$-0.62	$-0.70	$-1.16	$-0.07	$0.04	$0.08	$0.07	$-0.14	$-0.40
Net margin	-4.1%	-14.8%	-11.9%	-14.9%	-28.3%	-1.7%	0.9%	2.0%	0.9%	-0.2%	-2.6%
ROIC	—	-9.1%	-6.0%	-6.3%	-8.9%	-3.8%	-1.2%	1.6%	1.6%	0.8%	0.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $23.40, 46% above the current price; targets range from $19.00 to $35.00; the consensus rating is “Buy”; expected EPS is $0.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Neogenomics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Neogenomics pay a dividend?

Not currently.

Is Neogenomics a good stock to buy?

We do not give buy or sell advice. Neogenomics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

ULSUL Solutions2.6

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.